ACURX PHARMACEUTICALS RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHMon, 13 Apr 2026 02:39:19 +0200https://images.finanzen.net/images/finanzen_net_neu.gifACURX PHARMACEUTICALS RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netHealth~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx PharmaceuticalsTue, 18 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/health-holland-awards-another-innovative-research-grant-for-dna-pol-iiic-inhibitors-to-leiden-university-medical-center-and-acurx-pharmaceuticals-15287797
  • The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether ...

    ]]>https://www.finanzen.net/nachricht/aktien/health-holland-awards-another-innovative-research-grant-for-dna-pol-iiic-inhibitors-to-leiden-university-medical-center-and-acurx-pharmaceuticals-15287797Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business UpdateWed, 12 Nov 2025 13:01:00 +0100https://www.finanzen.net/nachricht/aktien/acurx-pharmaceuticals-inc-reports-third-quarter-results-and-provides-business-update-15266508

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" ...

    ]]>    https://www.finanzen.net/nachricht/aktien/acurx-pharmaceuticals-inc-reports-third-quarter-results-and-provides-business-update-15266508    Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority PathogensMon, 10 Nov 2025 14:00:00 +0100https://www.finanzen.net/nachricht/aktien/acurx-announces-publication-in-the-nature-communications-scientific-journal-documenting-its-unique-targeting-of-dna-pol-iiic-gram-positive-priority-pathogens-15249806
    • DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, ...

      ]]>https://www.finanzen.net/nachricht/aktien/acurx-announces-publication-in-the-nature-communications-scientific-journal-documenting-its-unique-targeting-of-dna-pol-iiic-gram-positive-priority-pathogens-15249806Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific ConferenceTue, 28 Oct 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/acurx-announces-new-data-on-its-dna-pol-iiic-inhibitor-antibiotics-demonstrating-a-potential-class-effect-of-gut-microbiome-selectivity-presented-at-idweek-2025-scientific-conference-15131662
      • Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC inhibitor, ibezapolstat (IBZ), has unique selective antibacterial activity in the gut which spares beneficial bile ...

        ]]>https://www.finanzen.net/nachricht/aktien/acurx-announces-new-data-on-its-dna-pol-iiic-inhibitor-antibiotics-demonstrating-a-potential-class-effect-of-gut-microbiome-selectivity-presented-at-idweek-2025-scientific-conference-15131662Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business UpdateMon, 27 Oct 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/acurx-pharmaceuticals-to-discuss-third-quarter-2025-financial-results-on-november-12-2025-conference-call-and-provide-business-update-15125426

        STATEN ISLAND, N.Y., Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" ...

        ]]>        https://www.finanzen.net/nachricht/aktien/acurx-pharmaceuticals-to-discuss-third-quarter-2025-financial-results-on-november-12-2025-conference-call-and-provide-business-update-15125426